<DOC>
	<DOCNO>NCT03028116</DOCNO>
	<brief_summary>The study single centre , phase I , double-blind , randomize , placebo-controlled trial explore safety immunogenicity single dose allantoic split inactivate seasonal influenza vaccine healthy adult .</brief_summary>
	<brief_title>Reactogenicity , Safety Immunogenicity Study Allantoic Split Inactivated Seasonal Influenza Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy volunteer sex age 1860 year . Persons seronegative A/H1N1 influenza virus , A/H3N2 type B ( antibody titer â‰¤1 : 10 , accord hemagglutinationinhibition ( HI ) assay determine ) . Literate willing provide write informed consent . A sign informed consent . Available anamnaze volunteer allergic reaction . Allergic reaction chicken protein , precede vaccination . Acute illness fever ( 37.0 C ) . Vaccination influenza 2012/2013 season . Seropositive volunteer A/H1N1 influenza virus , A/H3N2 type B ( antibody titer great 1:10 accord HI ) . Current recent ( within two week enrollment ) acute respiratory illness without fever . Hypersensitivity previous administration vaccine . History chronic alcohol abuse and/or illegal drug use . Any clinically significant abnormal laboratory finding . A positive pregnancy test woman childbearing potential . Administration immunosuppressive drug immune modify drug within 4 week prior study enrollment . Acute chronic clinically significant pulmonary disease , cardiovascular disease , gastrointestinal disease , liver disease , neurological illness , liver disease , blood disease , skin disorder , endocrine disorder , neurological illness psychiatric disorder determine medical history , physical examination clinical laboratory screening test , opinion investigator , might interfere study objective . History leukemia blood solid organ cancer . Seropositive HIV , hepatitis B surface antigen and/or hepatitis C antibody . Receipt antiviral , antibiotic , immunoglobulin blood product within 4 week prior study enrollment plan receipt product period subject participation study . Participation another clinical trial within previous three month plan enrollment trial period study . Subjects , opinion investigator , significantly increase risk noncooperation requirement study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>vaccine</keyword>
	<keyword>1 phase</keyword>
	<keyword>safety</keyword>
</DOC>